{"title":"A New Year, Newfangled COVID-19 Variant B.1.640.2 (IHU): What We Know So Far?","authors":"Suman Kumar Ray, Sukhes Mukherjee","doi":"10.2174/1871526522666220831101802","DOIUrl":null,"url":null,"abstract":"<p><p>A new COVID-19 variant that no one currently wants has emerged with the start of the new year. Omicron, which was first discovered in November of last year, was only just beginning to be understood when another strain uncovered in France made headlines. On January 4, 2022, news of the variant exploded on social media, but cases of what is now known as variant B.1.640.2 (IHU) were initially discovered about two months prior. Evidence is still being gathered, but internet misinformation regarding the latest coronavirus variety is already rampant, as it was with Omicron. The majority of existing vaccines target SARS-spike CoV-2's protein, which the virus utilizes to enter and infect cells. Epidemiologists and virologists worldwide are concerned about the virus' spike protein, which plays a key role in how your body identifies and reacts to the virus. Spike proteins are produced, recognized, and defended against by our immune system. Your body and the vaccines you have had injected into your system have a far harder time fighting the virus when the amino acids in a protein are altered or removed.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 2","pages":"e310822208284"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526522666220831101802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
A new COVID-19 variant that no one currently wants has emerged with the start of the new year. Omicron, which was first discovered in November of last year, was only just beginning to be understood when another strain uncovered in France made headlines. On January 4, 2022, news of the variant exploded on social media, but cases of what is now known as variant B.1.640.2 (IHU) were initially discovered about two months prior. Evidence is still being gathered, but internet misinformation regarding the latest coronavirus variety is already rampant, as it was with Omicron. The majority of existing vaccines target SARS-spike CoV-2's protein, which the virus utilizes to enter and infect cells. Epidemiologists and virologists worldwide are concerned about the virus' spike protein, which plays a key role in how your body identifies and reacts to the virus. Spike proteins are produced, recognized, and defended against by our immune system. Your body and the vaccines you have had injected into your system have a far harder time fighting the virus when the amino acids in a protein are altered or removed.
期刊介绍：
Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
